Lymphoma is a cancer of the lymphatic system. It develops in lymphocytes, which are a type of white blood cell. These cells help fight disease in the body and play an essential role in the body’s immune defenses. It most often spreads to the liver, bone marrow, or lungs. There are two main types of lymphoma: Hodgkin (HL) and non-Hodgkin lymphoma (NHL) (the most common type).
Chemotherapy is often used in the treatment of lymphoma. For some types of lymphoma, chemotherapy drugs are often combined with targeted treatments, such as Rituximab®. It has been noted that NHL becomes progressively chemoresistant while remaining responsive to external beam radiation therapy. Because of their remarkable effectiveness, radiolabeled tracers and drugs for imaging and therapy has been approved for use in patients with NHL. These drugs have proven to be remarkably effective and safe.
Europe: Hodgkin and non-Hodgkin vzw (BEL), Lymfklierkanker Vereniging Vlaanderen (LVV) (BEL), Lyle (DNK), Bulgarian Lymphoma Patients’ Association (BGR), Croatian Association of Leukemia and Lymphomas (HRV), Lymfom Help Czech Republic (SZE), France Lymphome Espoir (FRA), Deutsche Leukamie & Lymphom-Hilfe eV Germany (DEU), GAL (ITA), Linfovita (ITA), LPSA (LVA), HEMA (MKD), Drustvo bolnikov z limfomom Slovenia (SVN), AEAL (SPA)
Africa: Ensemble Contre le Lymphome (MAR)
Middle East: The Flute of Light (ISR)
LATAM: The Myeloma, Lymphoma & Leukaemia Foundation of Barbados (BRB), Asociación Gerardo Alfaro Mexico (MEX), FUNALINH Mexico (MEX), Linfomas Argentina (ARG), ABRALE (BRA)
Compassionate Use Program (CUP)
CUP enables patients with life-threatening diseases, such as advanced cancer, to resort to experimental treatments when standard anti-cancer solutions and access to clinical trials are not an option. Access to CUP programs depends on local regulations and can vary from one treatment to another.
Ask your referring physicians for more information regarding CUP.